ALPPS procedure for two stage liver resection

Lovekitties said:

Not much info
I have searched the internet and have found only one reference to the ALPPS procedure. It was a topic at a seminar in March of this year:

Moderators:
Dr. Oscar Andriani (Argentina)
Dr. Rogelio Traverso (Argentina)

Use of transplant associated techniques for complex hepatic resection
Dr. William Chapman (USA)

ALPPS - Associated liver partition and portal vein occlusion for stage hepatectomy: A new method to avoid postoperative liver failure
Dra. Victoria Ardiles (Argentina)

Near total liver resection for bilobar liver metastasis
Dr. Marcel Autran Machado (Brazil)

I was unable to find a doctor with the last name Eduardo in Argentina...there are lots with that as a first name.

I found nothing related to the hospital in Torino, Italy on the subject.

I would suggest that you get more details from the referring doctor.

sdp said:

aLPPS procedure - dr and hospital - dr Eduardo de santabaes,
Hi,

The procedure is currently not done in the USA . Dr geller, after seeing my scans etc feels I am the right candidate to opt for this procedure. Dr Eduardo santabanes does this procedure in Argentina. His bio data is as follows,

Biography - Eduardo de Santibaes, MD, PhD, FACS
 
 
Eduardo de Santibaes, MD, PhD, FACS
 
 
Eduardo de Santibaes graduated from the University of La Plata in Buenos Aires, Argentina, receiving the gold medal, the highest recognition awarded by the University for Outstanding Performance, his overall grade average being 9.27. He completed his surgical residency at the Hospital Italiano de Buenos Aires and later became chief of residents there.
He completed a research fellowship at the University Health Center of Pittsburgh School of Medicine (where Dr. Thomas Starzl was the chairman) prior to beginning his career as a surgeon specialized in transplantation and hepatobiliary cancer.
In 1988 he was recognized as one of Ten Outstanding Young People by the Junior Chamber of Buenos Aires, Argentina.
Together with his team, he performed the first adult liver transplantation in Argentina in January 1988 and the first liver living related donor transplantation in 1991.
Eduardo de Santibaes directed the laboratory of experimental surgery at the Hospital Italiano de Buenos Aires between 1989 and 1990. He and his team still continue their work there.
He was president of the Argentinean Transplantation Society between 1991 and 2000.
He created a fellowship in HPB and Liver Transplantation in 1992. Since then, he has been training surgeons from Argentina and other parts of the world.
In 2001 he founded the Argentinean Chapter of the Argentinean IHPBA (CA - IHPBA) together with other HPB surgeons.
He was President of the IHPBA Argentinean Chapter (2002- 2003)
He is Secretary-General of the Argentinean Academy of Surgery (2004 - 2008).
He is President-Elect of the 2008 Argentinean Congress of Surgery and Chairman of the IHPBA 2010 World Congress.
He has been the Chairman of the HPB and Liver Transplantation Unit at the Hospital Italiano de Buenos Aires since 1987. His unit has performed more than 700 transplants and over 1500 hepatic resections. The unit is the most active in Latin America, performing more than 1300 procedures per year.
He is an active clinical researcher and has contributed to the literature with his numerous papers and book chapters. He has given more than 500 national and international presentations and lectures. He is on the Editorial Board of many leading journals (including HPB Journal).
He became Full Professor and Chairman at the University of Buenos Aires in 2005.
He is a Fellow of the American College of Surgeons and active member of other professional organizations.
Dr Eduardo de Santibaes became an Honorary Fellow of the American Surgical Association in April, 2007.

Hospital is hospital Italiano,in buenos Aries, Argentina. Research paper for this is "Playing Poh-doh to prevent postoperative liver failure- the ALPPS approach"

I couldn't access the contents of this research paper.

Sdp

sdp said:

ALPPS
Hi,

Neither do I, am in hospital recovering from the operations.

I will describe it in detail later.

Still need to RFA one tumour later.

Sdp

sdp said:

ALPPS
Hi,

Neither do I, am in hospital recovering from the operations.

I will describe it in detail later.

Still need to RFA one tumour later.

Sdp

sdp said:

After two years

I didn't have to get an ALPPS at that time and the dr managed in one surgery

had recurrences thrice - in liver. - twice had ablation and one more time had a resection after the first resection

pl see my signature - also pl read on dr hans Schlitt formthe ALPPS 

Sdp, how much cimetidine and/or celebrex have you had so far?

sdp said:

cemitidine

i have had a few months of cemotidine 

 

but had a reoccurenxe few months ago even after the cemitidine

Those months of cimetidine should reduce, perhaps completely stop, new cancer seedlings  (for CA19-9 and CSLEX1/CEA both positive) that were generated during the treatment period but would do less for pre-existing seedlings, and nothing for later seedlings somewhat after the treatment period.    The perioperative period is a extra rich benefit period due to immune suppression from surgery.

In my wife's case, before her first surgery and any chemo drugs other than cimetidine, she had a substantial immunological event that necrosed some of her existing cancer metastases but not all. She had some other supplements too. She did not form new metastatic sites where oncologists would expect new mets to light up her PET scan in a year or so, spread from a large pre-existing para aortic lymph node cluster.  Any met formation that she gets now I interpret as likely the sprouting of old seedlings from before diagnosis (2010) because she has been on cimetidine continuously for 4+ years since diagnosis, and daily chemo 10 weeks later.  

Any cycling of even part of her immunochemo treatment is followed by rapid CEA rises, perhaps a met grown from the old seedlings.  These rises we've hammered back down with full formula plus celecoxib during the last 19 months although probably incomplete elimination.  We thin her blood to minimize the CV risks of celecoxib.